Curis Inc. (CRIS)

2.05
0.04 1.90
NASDAQ : Health Technology
Prev Close 2.09
Open 2.06
Day Low/High 2.00 / 2.09
52 Wk Low/High 0.60 / 2.90
Volume 44.95K
Avg Volume 185.60K
Exchange NASDAQ
Shares Outstanding 33.20M
Market Cap 67.07M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Curis Presentations Highlight Breadth Of Targeted Cancer Platform At 102nd AACR Annual Meeting 2011

Curis Presentations Highlight Breadth Of Targeted Cancer Platform At 102nd AACR Annual Meeting 2011

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in three poster...

Curis Stock Hits New 52-Week High (CRIS)

Curis Stock Hits New 52-Week High (CRIS)

Curis (Nasdaq:CRIS) hit a new 52-week high Tuesday as it changed hands at $3.67 compared with its previous 52-week high of $3.63. Curis is currently trading at $3.65 with 536,735 shares changing hands as of 1:46 p.m.

Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR Annual Meeting 2011

Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR Annual Meeting 2011

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data...

Curis Announces Presentations At 102nd American Association For Cancer Research Annual Meeting 2011

Curis Announces Presentations At 102nd American Association For Cancer Research Annual Meeting 2011

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its scientists will present preclinical data...

Curis To Present At The 10th Annual Needham Healthcare Conference

Curis To Present At The 10th Annual Needham Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Needham...

OptionsXpress, Rite Aid: Small-Cap Winners

OptionsXpress, Rite Aid: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Curis Stock Gaps Up On Today's Open (CRIS)

Curis Stock Gaps Up On Today's Open (CRIS)

Shares of Curis (Nasdaq:CRIS) were gapping up Monday morning with an open price 12.6% higher than Friday's closing price. The stock closed at $2.93 yesterday and opened today's trading at $3.30.

Roche, Curis Skin Cancer Drug Advances

Roche, Curis Skin Cancer Drug Advances

Roche may seek skin cancer drug approval based on positive results from mid-stage study.

Curis Announces Positive Results In Genentech Pivotal Phase II Clinical Trial Of GDC-0449 In Advanced Basal Cell Carcinoma

Curis Announces Positive Results In Genentech Pivotal Phase II Clinical Trial Of GDC-0449 In Advanced Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II...

Curis To Present At The Cowen And Company Healthcare Conference

Curis To Present At The Cowen And Company Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Cowen...

Curis To Present At The RBC Capital Markets Healthcare Conference

Curis To Present At The RBC Capital Markets Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the RBC...

Curis Reports Fourth Quarter And Year-End 2010 Financial Results

Curis Reports Fourth Quarter And Year-End 2010 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company developing next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the fourth quarter and fiscal year...

Curis To Present At The 13th Annual BIO CEO & Investor Conference

Curis To Present At The 13th Annual BIO CEO & Investor Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 13th Annual BIO CEO &...

Curis To Release Fourth Quarter And Year-end 2010 Financial Results And Hold Conference Call On February 10, 2011

Curis To Release Fourth Quarter And Year-end 2010 Financial Results And Hold Conference Call On February 10, 2011

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on ...

5 Bargain Biotech Stocks

5 Bargain Biotech Stocks

Life-saving companies such as Cerus and Curis could mean life-changing wealth for investors.

Curis Selects Dual Pi3 Kinase And HDAC Inhibitor CUDC-907 As Development Candidate

Curis Selects Dual Pi3 Kinase And HDAC Inhibitor CUDC-907 As Development Candidate

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally...

Curis To Present At Piper Jaffray 22nd Annual Healthcare Conference

Curis To Present At Piper Jaffray 22nd Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Piper...

Curis Presents CUDC-101 Phase I Clinical Data And CU-201 Preclinical Data At 22nd EORTC-NCI-AACR Symposium

Curis Presents CUDC-101 Phase I Clinical Data And CU-201 Preclinical Data At 22nd EORTC-NCI-AACR Symposium

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster ...

Curis To Present CUDC-101 Phase I Clinical Data And CU-201 Preclinical Data At The 22nd EORTC-NCI-AACR Symposium

Curis To Present CUDC-101 Phase I Clinical Data And CU-201 Preclinical Data At The 22nd EORTC-NCI-AACR Symposium

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Curis scientists and collaborators will...

Curis Awarded $500,000 In Grants Under The Patient Protection And Affordable Care Act

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been awarded two grants totaling...

Curis Reports Third Quarter 2010 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the third quarter ended...

Curis To Release Third Quarter 2010 Financial Results And Hold Conference Call On October 28, 2010

Curis To Release Third Quarter 2010 Financial Results And Hold Conference Call On October 28, 2010

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter 2010 financial results on...

10 Biotech Stocks Expected to at Least Double

The following 10 biotech stocks, though exceptionally risky, are expected to double, triple or quadruple in the next 12 months.

Curis Announces Genentech’s Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma

Curis Announces Genentech’s Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the...

Curis To Present At The 9th Annual BIO Investor Forum

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the 9 th...

Curis To Present At The Rodman & Renshaw 12th Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the Rodman...

Biotech Stock Mailbag Readers' Portfolio: Update

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 23% this year.

Curis Provides Update On Genentech’s Phase II Clinical Trial Of GDC-0449 In Advanced Ovarian Cancer Patients

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a...

Curis Reports Second Quarter 2010 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended...

Curis Announces Dosing Of First Patient In CUDC-101 Phase Ib Expansion Trial

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase...

TheStreet Quant Rating: D- (Sell)